

# Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Biotest
Enrollment	590 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Written informed consent.
- Hospitalized, adult (e 18 years of age) subject.
- Signs of inflammation based on C-reactive protein threshold level.
- Diagnosis of active community-acquired pneumonia (CAP) before hospital-admission or within 48 hours after admission.
- Radiological (or other imaging technology) evidence consistent with active pneumonia.

... and 1 more (see full listing online)

### Exclusion (24)

- For an incapacitated subject: any indication that the subject's presumed will would be against inclusion in the trial.
- Pregnant or lactating women.
- Subjects of childbearing potential not willing to use reliable contraceptive measures during the trial and for 15 weeks after the last IMP treatment.
- Subjects on ECMO at start of IMP treatment.
- Suspected hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP).

... and 19 more (see full listing online)

## Locations (147 total)

---

Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States  
University of California San Francisco-Fresno, Fresno, California, United States  
UC Davis Health, Sacramento, California, United States  
... and 144 more locations